Intelligence · Clinical pipeline
Phase III Pipeline Programs
Late-stage pivotal and registrational clinical programs nearing regulatory submission.
Quick answer
NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.
Top sponsors
- Takeda 393 programs
- United Therapeutics Europe 199 programs
- Anaxis Pharma 198 programs
- Chinese Academy of 189 programs
- Teva Pharma 148 programs
- Novartis India 145 programs
- BRIGHT MINDS BIOSCIENCES 139 programs
- PARItec 139 programs
- HOFFMANN-LA ROCHE 134 programs
- Regeneron UK 129 programs
- AstraZeneca 120 programs
- First People's Hospital 117 programs
Pipeline programs
-
1:1:1 Blood Transfusion Ratio
United Therapeutics Europe Ltd
Trauma
1 trial -
1mg elsunersen
Chongqing Precision Biotech Co., Ltd
Epileptic Encephalopathy
1 trial -
2 cycles induction chemotherapy
The First People's Hospital of Lianyungang
Locally Advanced Nasopharyngeal Carcinoma
1 trial -
2 mg Melatonin
United Therapeutics Europe Ltd
Anxiety
1 trial -
2-mg Intravitreous Aflibercept Injection
Regeneron UK Limited
Proliferative Diabetic Retinopathy
1 trial -
2.0 mg intravitreal aflibercept
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
2.16/VI/22
Cardiol Therapeutics
Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.
1 trial -
20 mg VEC-162
Vanda Pharmaceuticals Netherlands B.V.
Insomnia
1 trial -
20 mg sildenafil citrate by mouth
The First People's Hospital of Lianyungang
Pulmonary Hypertension
1 trial -
20-01/BetaSal-S
Alphapharm Pty Ltd
Chronic stable plaque psoriasis
1 trial -
20-AVP-786-306
Otsuka Beijing Research Institute
Agitation in Patients With Dementia of the Alzheimer's Type
1 trial -
2008-46
The First People's Hospital of Lianyungang
Colorectal Neoplasms
1 trial -
2015-1949
Ultragenyx UK Limited
Eosinophilic Gastrointestinal Disorders (EGIDs)
1 trial -
2016L10765-2
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Whooping Cough
1 trial -
20170724
Amgen
Secondary hyperparathyroidism (SHPT) in pediatric patients with chronic kidney disease (CKD) in hemodialysis
1 trial -
20170770
Amgen
Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
1 trial -
20186
Bayer AG
Treatment of children with chronic kidney disease and proteinuria
1 trial -
2019/2894
The George Institute
Patients with High Risk Neuroblastoma
1 trial -
2019/ABM/01/00074
Bial Portela & Companhia S.A.
Chronic obstructive pulmonary disease (COPD)
1 trial -
20190009
Amgen
Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation
1 trial -
20190172
Amgen
Colorectal Cancer (CRC)
1 trial -
20190360
Amgen
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia in older adults
1 trial -
20190529
Amgen
Juvenile psoriatic arthritis
1 trial -
20190531
Amgen
Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).
1 trial -
20200041
Amgen
Extensive stage small cell lung cancer (ES-SCLC)
1 trial -
2020HXFH037
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
2021/3336
The George Institute
Maintenance treatment in metastatic non-squamous lung cancer
1 trial -
2021/ABM/01/00010
Bial Portela & Companhia S.A.
Rare and ultra-rare glomerulonephritis
1 trial -
202100617
Disc Medicine
Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population
1 trial -
20210081
Amgen
Colorectal Cancer (CRC)
1 trial -
20210096
Amgen
Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression
1 trial -
20210098
Amgen
Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
1 trial -
20210184
Amgen
Chronic Weight Management
1 trial -
2022-009
Ningbo Cancer Hospital
metastatic breast cancer
1 trial -
20220043
Amgen
Osteogenesis Imperfecta
1 trial -
20220196
Amgen
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight
1 trial -
2023(728)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Carotid Stenosis
1 trial -
2023/3720 UMBRELLA
The George Institute
patients with a positive status for molecular residual disease (MRD) [MRD (+)] 2 to 5 months after the end of standard end of standard curative treatment
1 trial -
2023/3764
The George Institute
Metastatic renal cell carcinoma (mRCC)
1 trial -
20230005
Amgen
Metastatic castration-resistant prostate cancer (mCRPC)
1 trial -
20230016
Amgen
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
1 trial -
20230127
Amgen
Early-stage Non-squamous Non-small Cell Lung Cancer
1 trial -
20230225
Amgen
"Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"
1 trial -
20230227
Amgen
Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
1 trial -
20230239
Amgen
Metastatic castration-resistant prostate cancer (mCRPC)
1 trial -
20230309
Amgen
Relapsing-remitting Multiple Sclerosis
1 trial -
2024/4031
The George Institute
Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.
1 trial -
20240178
Amgen
Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.
1 trial
Frequently asked questions
How many Phase III pipeline programs are in the directory?
5,427 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.